Lipocine (LPCN) Return on Capital Employed (2013 - 2025)
Lipocine's (LPCN) quarterly Return on Capital Employed came in at 40.99% in Q3 2025, down 1489.0% YoY from 2.95% in Q3 2024, and down 32.9% on a QoQ basis from 30.84% in Q2 2025.
Lipocine (LPCN) Return on Capital Employed (2013 - 2025) Analysis & Trends
Lipocine (LPCN) has 13 years of Return on Capital Employed data on file, last reported at 40.99% in Q3 2025.
- Quarterly Return on Capital Employed fell 1489.0% year-over-year to 40.99% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 40.99% (down 1489.0% YoY) and the FY2024 annual result came in at 5.44%, up 5944.0% from the prior year.
- Return on Capital Employed retreated to 40.99% in Q3 2025, from 30.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.21% in Q3 2022 to a low of 84.4% in Q4 2023.
- A 5-year average of 31.36% and a median of 38.14% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed jumped 10515 bps — and 2023, when it slumped 7874 bps.
- Tracing LPCN's Return on Capital Employed over 5 years: stood at 7.71% in 2021, then slumped by 527 bps to 32.93% in 2022, then tumbled by 156 bps to 84.4% in 2023, then soared by 93 bps to 5.75% in 2024, then plunged by 613 bps to 40.99% in 2025.
- The last three Return on Capital Employed figures came in at 40.99% (Q3 2025), 30.84% (Q2 2025), and 32.01% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -40.99% |
| Jun 30, 2025 | -30.84% |
| Mar 31, 2025 | -32.01% |
| Dec 31, 2024 | -5.75% |
| Sep 30, 2024 | -26.10% |
| Jun 30, 2024 | -43.30% |
| Mar 31, 2024 | -45.61% |
| Dec 31, 2023 | -84.40% |
| Sep 30, 2023 | -70.53% |
| Jun 30, 2023 | -45.21% |
| Mar 31, 2023 | -39.37% |
| Dec 31, 2022 | -32.93% |
| Sep 30, 2022 | 8.21% |
| Jun 30, 2022 | 6.00% |
| Mar 31, 2022 | 6.72% |
| Dec 31, 2021 | 7.71% |
| Sep 30, 2021 | -38.66% |
| Jun 30, 2021 | -38.14% |
| Mar 31, 2021 | -50.71% |
| Dec 31, 2020 | -97.44% |